Creed Pettit’s Story

Creed Pettit, a 9 year boy from Miami, Florida had been slowly going blind since the day he was born. After a series of tests and analysis his doctors advised genetic testing. The outcomes of the test indicated that he had a rare genetic condition called Leber Congenital Amaurosis (LCA).

The mutation was identified in RPE65, a gene associated with retinal dystrophy, which leads to vision loss and complete blindness in certain patients.His genetic diagosntic results allowed his opthalomologist to treat him with Luxturna (voretigene neparvovec-rzyl), an FDA-approved gene therapy to treat children and adults with biallelic RPE65 mutation. Today Creed is able to see the world again.

Read Creed’s full story

Photo credit: https://www.aao.org/eye-health/patient-stories-detail/creed-gene-therapy#.Wvs-r4\_KCD8.facebook)

Summary

Genetic testing ensured identification of mutation in RPE65 as the responsible gene for patient’s blindness.

Subsequent gene therapy with Luxturna ensured restoration of sight.

\*More than 60% of cases of blindness among infants are caused by inherited eye diseases such as congenital cataracts, congenital glaucoma, retinal degeneration, optic atrophy and eye malformations

Reach us

About MedGenome

MedGenome is the leading solution provider of clinical genomics for Ophthalmologist across India, with an unmatched expertise and offerings, including clinical diagnosis, carrier testing, genetic counselling and validation of inheritance pattern.

\*Reference: https://my.clevelandclinic.org/health/articles/inherited-eye-disease